The PIONEER AF-PCI trial studied bleeding in patients with atrial fibrillation undergoing percutaneous coronary intervention with 3 different treatments. The study found that a rivaroxaban (Xarelto)-based strategy had a significant reduction of bleeding complications, explained Roxana Mehran, MD, FACC, FACP, professor of medicine and director of Interventional Cardiovascular Research and Clinical Trials at the Zena and Michael A. Weiner Cardiovascular Institute at Mount Sinai School of Medicine.
The PIONEER AF-PCI trial studied bleeding in patients with atrial fibrillation undergoing percutaneous coronary intervention with 3 different treatments. The study found that a rivaroxaban (Xarelto)-based strategy had a significant reduction of bleeding complications, explained Roxana Mehran, MD, FACC, FACP, professor of medicine and director of Interventional Cardiovascular Research and Clinical Trials at the Zena and Michael A. Weiner Cardiovascular Institute at Mount Sinai School of Medicine.
Transcript (slightly modified)
What was the point of the PIONEER AF-PCI study and what was the population being studied?
The PIONEER AF study was a study that was much needed in our literature. We have patients with atrial fibrillation undergoing PCI (percutaneous coronary intervention), and, frankly, we have a very, very difficult time in understanding how to treat these patients, on what kind of pharmacotherapy should these patients be on. Typically, there's this combination of warfarin—vitamin K antagonist warfarin—aspirin and clopidogrel, but, really, we know that stacking those therapies together increases the patient's risk for bleeding complications. And those bleeding complications can be quite significant.
So the alternative has been: can we drop aspirin? What about the novel anticoagulants? We really had no idea what to do and how to incorporate these approved agents that many patients with atrial fibrillation are already on and do not want to switch back to coumadin (warfarin). We really had no idea what to do with those patients, and so I think for the very first study with the novel anticoagulant, the PIONEER AF was very much needed. And now we really have some way to treat these patients.
PIONEER AF-PCI included 3 arms: 2 arms included rivaroxaban and the third arm was the current standard treatment. What were the outcomes of the study and what can you determine about the safety and efficacy of rivaroxaban?
What the PIONEER study showed was that a strategy that had a rivaroxaban-based strategy, the arm 1 and arm 2, had significant reduction of bleeding complications. These were clinically signficant bleeding requiring medical attention—most of them were that—or severe bleeding. And, in fact, there was a reduction in intracranial hemorrhage in the patients who received rivaroxaban therapy compared to a coumadin-based therapy or a vitamin k antagonist-based therapy. So the reduction in bleeding, which was the primary endpoint, was met.
Regarding the ischemic endpoints—stroke, stent thrombosis—we were not powered for those endpoints. You'd need 20,000 patients to show that. And so what we could say about the safety and efficacy—if you look at the safety profile regarding bleeding, we absolutely showed that. In fact, it was a superior safety profile in bleeding. But regarding the efficacy and reduction of stroke, the objective of the PIONEER study was not to look at that. What we were looking for was any kind of a signal and we didn't find one. Wide confidence intervals, no differences between stroke, stent thrombosis, ischemic complications.
So I think it's a profound study in showing a major reduction in bleeding when you avoid the triple therapy and you go with a novel anticoagulant during that period of time in the peri-PCI period of time of 6 to 12 months.
Contributor: More Informed Management of Preeclampsia Is Necessary
November 29th 2023At present, it is difficult for clinicians to identify patients at greatest risk for developing preeclampsia with severe features and tailor treatment plans for them; this difficulty increases costs significantly.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Provisional CDC data show that US babies gained roughly a year in life expectancy in 2022; study findings indicate that the COVID-19 pandemic significantly raised the risk of preterm birth for expectant California mothers; New York Attorney General Letitia James said about 4 million New Yorkers were affected by a data breach of the medical transcription company Perry Johnson & Associates.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Gene Therapy Success in UK Likely Depends on Overcoming Education, Psychological Support Challenges
November 27th 2023Education, psychological support, and implementation guidance are the top unmet needs identified by investigators from the United Kingdom concerning gene therapy use for hemophilia.
Read More